Biomedical salvation – medicine, biology – the pharmaceutical industry – PEM Fas
If you have a good business overseas before the foundation of the acquired companies have good technology, good products, while the parent company can be formed with existing resources and complementary channels, then the overseas M & A is still very worth the effort. Institutional investors generally optimistic about the situation in 2009, the Chinese medicine, but that the investment too risky biomedical
Global economic winter season, the health industry as a haven of relative warmth, triggering concern from various quarters of funds, but the sun there are tough biomedical sub-sector trend.
On December 16 in Beijing, China held its third investment and financing medical and health industry summit, the participants on behalf of investment institutions investing in Outlook 2009 when the general optimism about the direction of the situation of Chinese medicine, especially Medical Devices , Social security-related projects, but for biomedical and New Drugs In the field, most agencies believe that too risky. China has the opportunity
Past six months, the financial turmoil has resulted in large-scale funds shrink, medicine project stalled, unable to find willing investors, or the system Pharmaceutical companies Trade flows and thus breaking into the quagmire of biological phenomena in the United States is not accidental.
New York Stock Exchange, Yang Ge, chief representative of Beijing office told reporters on how to deal with stock fall due, fail to attract New shareholders face the issue of delisting of the company, the Nasdaq temporarily freeze "1 U.S. dollar delisting rules", the NYSE and other institutions are trying to find a number of measures to help tide over their difficulties. Feedback from U.S. sources said, these measures do not help for biotech companies, small biotechnology companies not listed may be more difficult situation. But in China, these companies are relatively good, the view that the effect may appear sluggish.
"China can be said that drug research and development of the 'Shenzhen Special Economic Zone'." Eli Lilly Asia, Shi Yi, general manager of venture capital funds are very confident that the new drug development is a high-risk process, but also represents a relatively high income. For new drug development in China, especially the development of new drugs in the biological area is no problem, because there is policy support; while before China did not become a qualitative model, will not be set pattern yoke together, these factors can be expected in the next 10 During the year a new generation of biotechnology companies in China was born.
Other participating institutions view also: China's biotechnology talent pool is sufficient, if well integrated with the capital, the outlook is very bright.
One in private equity funds told reporters before the Fund A shares over the operation, the situation is not clear, therefore more suitable as long-term investment. And they have expressed strong interest in medicine.
"Valuations are relatively low now, more stringent conditions for investors, many of the capital are 'clutching his purse'. In fact, neither the private equity or venture capital, this year there is a rational investment return process. "One participant pointed out.
Shot international mergers and acquisitions? So, at this time the Chinese have a chance to go abroad to buy the dips, take the opportunity to introduce foreign advanced technology and product?
This, Hong Kong, China Renaissance Capital Investment Co., Ltd. Beijing Office Chief Representative, said Chen Min question: China is indeed now have the opportunity to buy, but not really need to buy? Human, financial, material, research, production and marketing is not ready? "The situation we face now different from before. Before to buy foreign companies may not want to sell because of policy constraints, conditions have now bought, and it represents our ability to manage the acquisition to the company? Addition, our M & What is the purpose? economically sustainable ways? "These are all need to think.
Global venture capital fund DFJ partner Xiao Yuan pointed out that the implementation of its handling of the merger cases, 10 in the end, but one or two to complete the merger, and complete, you can achieve synergies, but also one or two companies as, very often the result was 1 +1 <2.
We are high quality suppliers, our products such as PEM Fastener Supplier , Metal Fabrication for oversee buyer. To know more, please visits china machining parts.
Processing your request, Please wait....
